Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor?

Donatella Gambini; Elisa Locatelli; Umberto Gianelli; Claudia Bareggi; Barbara Galassi; Roberto Visintin; Sara Massironi; Paolo G. Dell'orto; Maurizio Tomirotti

Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor?

Donatella Gambini, Elisa Locatelli, Umberto Gianelli, Claudia Bareggi, Barbara Galassi, Roberto Visintin, Sara Massironi, Paolo G. Dell'orto, Maurizio Tomirotti

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant sideeffects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.

Original language	English
Pages (from-to)	7361-7365
Number of pages	5
Journal	Anticancer Research
Volume	34
Issue number	12
Publication status	Published - Dec 1 2014

Keywords

Neuroendocrine markers
Predictive markers
Renal cell carcinoma
Sunitinib

ASJC Scopus subject areas

Cancer Research
Oncology
Medicine(all)

Fingerprint Dive into the research topics of 'Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor?'. Together they form a unique fingerprint.

Cite this

Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers : A new predictive factor? / Gambini, Donatella; Locatelli, Elisa; Gianelli, Umberto ; Bareggi, Claudia; Galassi, Barbara; Visintin, Roberto; Massironi, Sara; Dell'orto, Paolo G.; Tomirotti, Maurizio.

In: Anticancer Research, Vol. 34, No. 12, 01.12.2014, p. 7361-7365.

Research output: Contribution to journal › Article › peer-review

Gambini, Donatella ; Locatelli, Elisa ; Gianelli, Umberto ; Bareggi, Claudia ; Galassi, Barbara ; Visintin, Roberto ; Massironi, Sara ; Dell'orto, Paolo G. ; Tomirotti, Maurizio. / Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers : A new predictive factor?. In: Anticancer Research. 2014 ; Vol. 34, No. 12. pp. 7361-7365.

@article{c0a373cad9ec445d943b2db76c080793,

title = "Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor?",

abstract = "Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant sideeffects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.",

keywords = "Neuroendocrine markers, Predictive markers, Renal cell carcinoma, Sunitinib",

author = "Donatella Gambini and Elisa Locatelli and Umberto Gianelli and Claudia Bareggi and Barbara Galassi and Roberto Visintin and Sara Massironi and Dell'orto, {Paolo G.} and Maurizio Tomirotti",

year = "2014",

month = dec,

day = "1",

language = "English",

volume = "34",

pages = "7361--7365",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers

T2 - A new predictive factor?

AU - Gambini, Donatella

AU - Locatelli, Elisa

AU - Gianelli, Umberto

AU - Bareggi, Claudia

AU - Galassi, Barbara

AU - Visintin, Roberto

AU - Massironi, Sara

AU - Dell'orto, Paolo G.

AU - Tomirotti, Maurizio

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant sideeffects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.

AB - Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant sideeffects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.

KW - Neuroendocrine markers

KW - Predictive markers

KW - Renal cell carcinoma

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84918502593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918502593&partnerID=8YFLogxK

M3 - Article

C2 - 25503173

AN - SCOPUS:84918502593

VL - 34

SP - 7361

EP - 7365

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -

Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor?

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this